- Home
- / Excision BioTherapeutics
Excision BioTherapeutics
Total Funding
$10.8 M
Excision BioTherapeutics Summary
Company Summary
- Overview
- Excision BioTherapeutics is a biotech company focused on developing gene editing solutions for the treatment of diseases caused by viral infections. Its main therapeutic is the HIV CRISPR Cas9/gRNA multiplex biologic for the eradication of latent HIV.
- Type
- Private
- Status
- Active
- Founded
- 2015
- HQ
- San Francisco, CA, US | view all locations
- Website
- https://www.excision.bio
- Cybersecurity rating
- Sectors
Table of Contents
Key People
Lisa Danzig, Chief Medical Officer
Jennifer Gordon, Senior Vice President, R&D
Lucas Buchheim-Jurisson, Associate Director, Corporate Strategy
LocationsView all
2 locations detected
San Francisco, CA HQ
United States
988 Market St, San Francisco
Philadelphia, PA
United States
Student Center South, 1755 N 13th St #274